In the broader markets, the BSE MidCap index added 0.7 per cent while the BSE SmallCap index gained 1.2 per cent.
The pharmaceutical company has fixed Tuesday, January 11, 2022, as the 'record date' for the members entitlement of sub-divided shares.
Ipca Labs has tripled in the last one year from the lows of Rs 817 and continues to hold the same strength and momentum. Charts indicate more headroom from the current levels
In Q2FY21, the company's Ebitda margins are likely to improve 740 basis points YoY to 28 per cent
With markets recovering, midcaps have also rebounded and in fact, have outperformed benchmark indices by a good margin in the last two months
There is a lot of uncertainty and clear trend is not visible on the charts
The SGX Nifty is up around 170 points from yesterday's close and is indicating an open at around 9,980 levels for the Nifty today
SGX Nifty, which is up 130 points, is indicating a stronger opening for the Indian indices today
Ipca's Zerodol brand and its multiple variants used in treating pain and inflammation are an example of how this trend is playing out
Technical Calls by Gaurav Garg, Head of Research at CapitalVia Global Research Limited- Investment Advisor
Bharti Airtel's move remained resilient during the downtrend which the market witnessed in the current calendar year
The primary trend of Ipca Lab's stock has been bullish with higher tops and higher bottoms on the weekly and monthly charts
The medicine is considered one of the possible treatments for the Covid-19
Ipca's first half performance holds testimony to its robust growth with India business growing in mid-teens
The United States Food and Drug Administration (USFDA) inspection of its Piparia (Silvassa) formulations manufacturing unit in August resulted in three observations, it added.
Resolution of FDA issues a key positive for the stock and should be sorted in FY16, so investors should be patient
The acquisition of a majority stake in Bayshore will allow Ipca to commercialise its registered generic drug products in the US market
Global Fund will not source ACTs because of warning letter issued by USFDA